Milameline

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Milameline
Milameline.png
Clinical data
ATC code
  • None
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ECHA InfoCard 100.220.595
Chemical and physical data
Formula C8H14N2O
Molar mass 154.21 g/mol
3D model (Jmol)

Milameline (CI-979, PD-129,409, RU-35,926) is a non-selective muscarinic acetylcholine receptor partial agonist with cognition-acting properties that was being investigated for the treatment of Alzheimer's disease, but produced poor results in clinical trials and was subsequently discontinued.[1]

See also[edit]

References[edit]

  1. ^ Sedman AJ, Bockbrader H, Schwarz RD (1995). "Preclinical and phase 1 clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease". Life Sciences. 56 (11-12): 877–82. doi:10.1016/0024-3205(95)00023-Y. PMID 10188788.